Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06385275
PHASE1/PHASE2

The Role of Vitamin K on Knee Osteoarthritis Outcomes

Sponsor: Boston University

View on ClinicalTrials.gov

Summary

The appropriate form and dosing of vitamin K to benefit relevant outcomes in knee osteoarthritis (OA) are not known. In intervention studies for conditions other than knee OA (e.g., prevention of cardiovascular disease), the most commonly used forms and doses include phylloquinone (vitamin K1; 1000µg or 500µg daily) or menaquinone-7 (MK-7 or vitamin K2; 300µg daily). However, whether these doses are adequate to increase vitamin K to levels that ameliorate risk of adverse OA outcomes is not known. Furthermore, although some studies suggest enhanced bioavailability of MK-7 over vitamin K1, as well as extra-hepatic effects, whether this is relevant for an older population with knee OA is not known, The overall goal of this pilot randomized clinical trial (RCT) is to test different subtypes and doses of vitamin K supplementation in older adults with knee OA and to measure changes in relevant biochemical measures.

Key Details

Gender

All

Age Range

60 Years - Any

Study Type

INTERVENTIONAL

Enrollment

55

Start Date

2025-06-03

Completion Date

2026-12

Last Updated

2026-01-23

Healthy Volunteers

No

Interventions

DRUG

Vitamin K1 500 µg

One pill daily for 4 weeks.

DRUG

K1 1000 µg

One pill daily for 4 weeks.

DRUG

Vitamin K2 (MK-7) 300 µg

One pill daily for 4 weeks.

OTHER

Placebo

Placebo pill daily for 4 weeks.

Locations (1)

Boston Medical Center, Rheumatology Clinic

Boston, Massachusetts, United States